Skip to main content
. 2017 Jan 28;8(9):14306–14313. doi: 10.18632/oncotarget.14882

Figure 2. Western blotting analysis with representative sera in ELISA.

Figure 2

Lanes 1-6: six representative pSS sera that were anit-MDM2 positive in ELISA and also had strong reactivity with MDM2 recombinant protein in western blotting analysis. Lanes 7-9: three randomly selected anti-MDM2 negative NHS by ELISA had negative reactivity with MDM2 recombinant protein.